Skip to main content

Olympia A Clinical Trial

Image placeholder title
Breast Cancer Treatment

PARP Inhibitors improve outcomes in BRCA mutated breast cancer. FDA approves Lynparza for treatment of TNBC and early stage breast cancer.

By Dr. C.H. Weaver M.D.Apr 30, 2022